Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response After Vaccination and Thus Are at High Risk of Developing Severe COVID-19
Condition: COVID-19, SARS-CoV-2 Interventions: Biological: Biological: AZD3152; Biological: Biological: Placebo Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials
The Prevalence Evaluation of Systemic Lupus Erythematosus in Russian Patients With Reproductive Issues (PRISMA)
Condition: Systemic Lupus Erythematosus Intervention: Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials
Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response After Vaccination and Thus Are at High Risk of Developing Severe COVID-19
Conditions: COVID-19, SARS-CoV-2 Interventions: Biological: Biological: AZD3152; Biological: Biological: Placebo Sponsors: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials
The Prevalence Evaluation of Systemic Lupus Erythematosus in Russian Patients With Reproductive Issues (PRISMA)
Conditions: Systemic Lupus Erythematosus Sponsors: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials
SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes
Conditions: Type2diabetes; PreDiabetes; Renal Failure Interventions: Drug: Dapagliflozin (Forxiga®); Drug: Placebo matching Dapaglifolzin; Behavioral: Lifestyle Intervention Sponsors: University Hospital Tuebingen; German Federal Ministry of Education and Research; German Center for Diabetes Research; AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials
SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes
Conditions: Type2diabetes; PreDiabetes; Renal Failure Interventions: Drug: Dapagliflozin (Forxiga ®); Drug: Placebo matching Dapaglifolzin; Behavioral: Lifestyle Intervention Sponsors: University Hospital Tuebingen; German Federal Ministry of Education and Research; German Center for Diabetes Research; AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials
Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease
Condition: Crohn's Disease Interventions: Drug: AZD7798; Drug: [11C]AZ14132516 Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials
Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease
Conditions: Crohn ' s Disease Interventions: Drug: AZD7798; Drug: [11C]AZ14132516 Sponsors: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials
Retrospective Medical Chart Review Study to Describe the Experience of SLE Patients Treated With Anifrolumab in the Early Access Programs
Condition: Systemic Lupus Erythematosus Intervention: Other: None (Observational study) Sponsors: AstraZeneca; CernerEnviza Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by Electroporation Ablation
Condition: BCLC A Hepatocellular Carcinoma Non-resectable and Not Amenable for RFA Intervention: Drug: Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting Sponsors: Assistance Publique - Hôpitaux de Paris; AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
